Skip to content

US · SHPH · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) intrinsic value and stock valuation

$3.49as of 2026-11-21 · Mkt cap 2.55M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Shuttle Pharmaceuticals Holdings, Inc. DCF and intrinsic value

InvestorsCraft values SHPH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SHPH’s statements →

Shuttle Pharmaceuticals Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Gaithersburg, MD 20879 shuttlepharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-11.72M
20172025
Free cash flow
-$-9.48M
20172025
Total equity
$2.25M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-11.92M-$-7.7M-$-5.89M-$-2.34M-$-1.74M
Net income-$-11.72M-$-9.14M-$-6.59M-$-5M-$-1.15M
EPSd-$-73.25M-$-8.87M-$-4.14M-$-4.81M-$-845.59K
Operating cash flow-$-9.48M-$-7.33M-$-5.58M-$-2.67M-$-300K
Capital expenditure$0.00$0.00-$-20K$0.00$0.00
Free cash flow-$-9.48M-$-7.33M-$-5.6M-$-2.67M-$-300K
Total assets$10.5M$2.51M$5.95M$8.65M$650K
Total debt$230K$1.17M$1.09M$750K$980K
Net debt-$-100K-$-750K-$-1.49M-$-7.67M$470K
Total equity$2.25M$710K$4.06M$7.68M-$-1.63M
Cash and short-term investments$330K$1.92M$5.46M$8.42M$500K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$10K$60K
Gross profit$0.00$0.00$0.00-$-10K-$-60K
Research and development expenses$4.05M$3.62M$3.52M$1.05M$1.02M
Selling, general and administrative expenses$7.86M$4.08M$2.38M$1.29M$720K
Other expenses$0.00$0.00$0.00$0.00-$-60K
Operating expenses$11.9M$7.7M$5.89M$2.34M$1.68M
Cost and expenses$11.9M$7.7M$5.89M$2.34M$1.74M
Interest income$0.00$40K$80K$0.00$0.00
Interest expense$70K$1.36M$2.6M$670K$50K
Depreciation and amortization$290K$10K$10K$10K$60K
Ebitda-$-11.36M-$-7.78M-$-3.99M-$-4.32M-$-1.04M
Operating income-$-11.92M-$-7.7M-$-5.89M-$-2.34M-$-1.74M
Total other income/expenses, net$200K-$-1.45M-$-700K-$-2.65M$590K
Income before tax-$-11.72M-$-9.14M-$-6.59M-$-5M-$-1.15M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.72M-$-9.14M-$-6.59M-$-5M-$-1.15M
Weighted average shares outstanding$160K$1.03M$1.59M$1.04M$1.36M
Weighted average diluted shares outstanding$160K$1.03M$1.59M$1.04M$1.36M
Balance sheet
20252024202320222021
Cash and short-term investments$330K$1.92M$5.46M$8.42M$500K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$500K$2.21M$5.59M$8.58M$510K
Property, plant and equipment, net$120K$300K$360K$70K$140K
Goodwill and intangible assets$9.84M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$9.97M$300K$360K$80K$140K
Total assets$10.5M$2.51M$5.95M$8.65M$650K
Accounts payable$1.45M$600K$280K$130K$830K
Short-term debt$80K$940K$650K$750K$920K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.97M$1.53M$1.04M$980K$2.22M
Long-term debt$150K$240K$440K$0.00$60K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$250K$260K$850K-$0.00$60K
Capital lease obligations$230K$300K$360K$60K$130K
Total liabilities$8.22M$1.8M$1.9M$980K$2.28M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-46.3M-$-34.58M-$-25.43M-$-8.89M-$-5.8M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$20K
Total equity$2.25M$710K$4.06M$7.68M-$-1.63M
Total investments$0.00$0.00$2.89M$0.00$0.00
Total debt$230K$1.17M$1.09M$750K$980K
Net debt-$-100K-$-750K-$-1.49M-$-7.67M$470K
Cash flow statement
20252024202320222021
Net income-$-11.72M-$-9.14M-$-6.59M-$-5M-$-1.15M
Depreciation and amortization$290K$10K$10K$10K$60K
Stock-based compensation$930K$260K$180K$240K$910K
Change in working capital$540K$140K$220K-$-460K$520K
Accounts receivable$0.00$10K-$-10K$0.00$210K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$420K$310K$150K-$-370K$310K
Net cash provided by operating activities-$-9.48M-$-7.33M-$-5.58M-$-2.67M-$-300K
Investments in property, plant and equipment-$-10K$0.00-$-20K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-3.06M$2.92M-$-2.83M$0.00$0.00
Common stock issued$11.2M$3.99M$0.00$10M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11M$3.76M$2.57M$10.6M$690K
Net change in cash-$-1.59M-$-660K-$-5.84M$7.91M$390K
Cash at end of period$330K$1.92M$2.58M$8.42M$500K
Operating cash flow-$-9.48M-$-7.33M-$-5.58M-$-2.67M-$-300K
Capital expenditure$0.00$0.00-$-20K$0.00$0.00
Free cash flow-$-9.48M-$-7.33M-$-5.6M-$-2.67M-$-300K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Shuttle Pharmaceuticals Holdings, Inc.

        Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.

        CEO
        Christopher Robert Cooper
        Employees
        2
        Beta
        1.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Shuttle Pharmaceuticals Holdings, Inc. (SHPH)?

        InvestorsCraft does not currently publish an intrinsic value for SHPH. How the IC value is calculated.

        Is SHPH undervalued?

        InvestorsCraft does not publish an undervaluation signal for SHPH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.